(Q35866145)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Modern management of pancreatic carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Goldstein D

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Carroll S

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Keogh G

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 August 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

Internal Medicine Journal

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

475-481

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Risk of pancreatic adenocarcinoma in chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Chronic pancreatitis and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Genetic alterations in pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Hospital volume and surgical mortality in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

Chemotherapy in the treatment of cancer of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1444-0903.2004.00658.X

10.1111/J.1444-0903.2004.00658.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15317546%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference